A number of brokerages have recently commented on AVRO. Zacks Investment Research downgraded Avrobio from a “hold” rating to a “sell” rating in a research note on Tuesday, February 12th. Leerink Swann reduced their price target on Avrobio from $27.00 to $19.00 and set a “market perform” rating for the company in a report on Thursday, January 17th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Avrobio in a report on Tuesday, January 15th.
Shares of Avrobio Inc (NASDAQ:AVRO) have received a consensus recommendation of “Buy” from the nine research firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $34.25.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AVRO. Aisling Capital Management LP acquired a new position in Avrobio in the 4th quarter worth about $12,271,000. Wells Fargo & Company MN acquired a new position in Avrobio in the 3rd quarter worth about $19,064,000. BlackRock Inc. raised its holdings in Avrobio by 4,239.1% in the 3rd quarter. BlackRock Inc. now owns 375,941 shares of the company’s stock worth $19,500,000 after purchasing an additional 367,277 shares during the period. JPMorgan Chase & Co. raised its holdings in Avrobio by 65.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 537,322 shares of the company’s stock worth $27,871,000 after purchasing an additional 211,847 shares during the period. Finally, Vanguard Group Inc raised its holdings in shares of Avrobio by 374.5% during the third quarter. Vanguard Group Inc now owns 246,738 shares of the company’s stock valued at $12,798,000 after acquiring an additional 194,738 shares during the last quarter. 69.47% of the stock is owned by institutional investors.
Shares of AVRO opened at $14.21 on Monday. Avrobio has a 52 week low of $11.85 and a 52 week high of $53.70.
Avrobio Company Profile
AVROBIO, Inc, a clinical stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company's gene therapies employ hematopoietic stem cells that are extracted from the patient and modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease.
Featured Article: What is the Ex-Dividend Date in Investing?